Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus salivarius subsp. salicinius AP-32 metabolites
- Development stage
- Unknown
- Lead developer
- Bioflag Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical, Vaginal
01
Overview
Lactobacillus salivarius subsp. salicinius AP-32 metabolites are postbiotic components derived from the fermentation of the specific probiotic strain AP-32, developed by Glac Biotech. These metabolites include organic acids, bacteriocins, and other bioactive compounds that exhibit potent antimicrobial properties against oral and vaginal pathogens, such as *Streptococcus mutans* and *Candida albicans*. The metabolites function by inhibiting pathogen adhesion, disrupting biofilm formation, and modulating local immune responses. They are primarily utilized in oral care products and feminine hygiene supplements to maintain microbial balance and prevent infections.
- Brand names
- Totipro
- Other names
- AP-32 postbioticsAP32 postbioticsAP 32 postbioticsLactobacillus salivarius AP-32 fermentateLactobacillus salivarius subsp. salicinius AP-32
Beyond the preview
Go deeper on Lactobacillus salivarius subsp. salicinius AP-32 metabolites.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus salivarius subsp. salicinius AP-32 metabolites.